{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360865814745367680.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1186/s12882-024-03494-1"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/content/pdf/10.1186/s12882-024-03494-1.pdf"}},{"identifier":{"@type":"URI","@value":"https://link.springer.com/article/10.1186/s12882-024-03494-1/fulltext.html"}},{"identifier":{"@type":"DOI","@value":"10.21203/rs.3.rs-3341887/v1"}}],"resourceType":"学術雑誌論文(journal article)","dc:title":[{"@value":"Nephrotic syndrome with acute kidney injury due to combination therapy of immune checkpoint inhibitors: a case report and review of the literature"}],"description":[{"type":"abstract","notation":[{"@value":"<jats:title>Abstract</jats:title>\n                  <jats:sec>\n                    <jats:title>Background</jats:title>\n                    <jats:p>Recent studies have focused on immune checkpoint inhibitors. Renal complications associated with the use of immune checkpoint inhibitors are uncommon compared with other immune-related adverse events. Acute interstitial nephritis accounts for most of these renal complications, with nephrotic syndrome quite rare. We herein report a case of nephrotic syndrome associated with immune checkpoint inhibitors that was more severe than that in previous cases. By comparing this case with previous reports, the possible reasons for the particular severity of this case are discussed.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation</jats:title>\n                    <jats:p>A 75-year-old man developed nephrotic syndrome with acute kidney injury after the first combination therapy of nivolumab and ipilimumab for malignant pleural mesothelioma. The results of a kidney biopsy indicated minimal change disease with mild atherosclerosis, acute interstitial nephritis, and fusion of nearly all podocyte foot processes. Nivolumab and ipilimumab therapy were stopped, and treatment with corticosteroids was initiated. We investigated previously reported cases of nephrotic syndrome using immune checkpoint inhibitors. Seventeen cases of immune checkpoint inhibitor-related nephrotic syndrome, including ours, have been reported. Two of the 17 patients with immune checkpoint inhibitor-related nephrotic syndrome required hemodialysis treatment for acute kidney injury. Unlike many previously reported cases, the present patient was administered two different immune checkpoint inhibitors, which may be one of the reasons for the development of severe nephrotic syndrome.</jats:p>\n                  </jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions</jats:title>\n                    <jats:p>In addition to previously reported risk factors, immune checkpoint inhibitor combination therapy can exacerbate nephrotic syndrome compared to immune checkpoint inhibitor monotherapy.</jats:p>\n                  </jats:sec>"}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380865814745367819","@type":"Researcher","foaf:name":[{"@value":"Ryosuke Saiki"}]},{"@id":"https://cir.nii.ac.jp/crid/1420001326226540160","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"90742247"},{"@type":"NRID","@value":"1000090742247"},{"@type":"NRID","@value":"9000001092736"},{"@type":"NRID","@value":"9000415046098"},{"@type":"NRID","@value":"9000016665448"},{"@type":"NRID","@value":"9000411647703"},{"@type":"NRID","@value":"9000414521440"},{"@type":"RESEARCHMAP","@value":"https://researchmap.jp/katayamk"}],"foaf:name":[{"@value":"Kan Katayama"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367681","@type":"Researcher","foaf:name":[{"@value":"Haruko Saiki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367687","@type":"Researcher","foaf:name":[{"@value":"Ayumi Fukumori"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367810","@type":"Researcher","foaf:name":[{"@value":"Kayo Tsujimoto"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367818","@type":"Researcher","foaf:name":[{"@value":"Masahiro Yamawaki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367696","@type":"Researcher","foaf:name":[{"@value":"Fumika Tanaka"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367817","@type":"Researcher","foaf:name":[{"@value":"Daisuke Takahashi"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367816","@type":"Researcher","foaf:name":[{"@value":"Keiko Oda"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367683","@type":"Researcher","foaf:name":[{"@value":"Yasuo Suzuki"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367684","@type":"Researcher","foaf:name":[{"@value":"Tomohiro Murata"}]},{"@id":"https://cir.nii.ac.jp/crid/1380865814745367704","@type":"Researcher","foaf:name":[{"@value":"Kaoru Dohi"}]}],"publication":{"publicationIdentifier":[{"@type":"EISSN","@value":"14712369"}],"prism:publicationName":[{"@value":"BMC Nephrology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2024-02-09","prism:volume":"25","prism:number":"1"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","dc:rights":["https://creativecommons.org/licenses/by/4.0","https://creativecommons.org/licenses/by/4.0"],"url":[{"@id":"https://link.springer.com/content/pdf/10.1186/s12882-024-03494-1.pdf"},{"@id":"https://link.springer.com/article/10.1186/s12882-024-03494-1/fulltext.html"}],"createdAt":"2024-02-09","modifiedAt":"2024-02-09","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Immune%20checkpoint%20inhibitors","dc:title":"Immune checkpoint inhibitors"},{"@id":"https://cir.nii.ac.jp/all?q=Nivolumab%E2%80%93%20ipilimumab","dc:title":"Nivolumab– ipilimumab"},{"@id":"https://cir.nii.ac.jp/all?q=Nephrotic%20syndrome","dc:title":"Nephrotic syndrome"},{"@id":"https://cir.nii.ac.jp/all?q=Case%20Report","dc:title":"Case Report"},{"@id":"https://cir.nii.ac.jp/all?q=RC870-923","dc:title":"RC870-923"},{"@id":"https://cir.nii.ac.jp/all?q=Minimal%20change%20disease","dc:title":"Minimal change disease"},{"@id":"https://cir.nii.ac.jp/all?q=Diseases%20of%20the%20genitourinary%20system.%20Urology","dc:title":"Diseases of the genitourinary system. Urology"},{"@id":"https://cir.nii.ac.jp/all?q=Acute%20kidney%20injury","dc:title":"Acute kidney injury"}],"project":[{"@id":"https://cir.nii.ac.jp/crid/1040569382227330432","@type":"Project","projectIdentifier":[{"@type":"KAKEN","@value":"21K08255"},{"@type":"JGN","@value":"JP21K08255"},{"@type":"URI","@value":"https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-21K08255/"}],"notation":[{"@language":"ja","@value":"巣状糸球体硬化症発症におけるポドサイト特異的遺伝子CRB2の機能解明"},{"@language":"en","@value":"Elucidation of the function of podocyte-specific gene CRB2 in the development of focal segmental glomerulosclerosis"}]}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050010997614768128","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["references"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Pembrolizumab-associated nephrotic syndrome recovered from transient hemodialysis in a patient with lung cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360011146145302144","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: Report of 21 cases and review of the literature"}]},{"@id":"https://cir.nii.ac.jp/crid/1360013172348379392","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database"}]},{"@id":"https://cir.nii.ac.jp/crid/1360282589017259008","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294645157044096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association between immune-related adverse events and long-term survival outcomes in patients treated with immune checkpoint inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298761846900480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"First-line Immunotherapy-based Combinations for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302870444138624","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302870445136256","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360302870445300480","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Case Report: THSD7A-Positive Membranous Nephropathy Caused by Tislelizumab in a Lung Cancer Patient"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576123223720576","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Renal Vasculitis and Pauci-immune Glomerulonephritis Associated With Immune Checkpoint Inhibitors"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346088224768","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Analysis of the association between prospectively collected immune-related adverse events and survival in patients with solid tumor treated with immune-checkpoint blockers, taking into account immortal-time bias"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346089126272","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Tubular Dysfunction in Nephrotic Syndrome: Incidence and Prognostic Implications"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584346089564160","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Response to combined ipilimumab and nivolumab after development of a nephrotic syndrome related to PD-1 monotherapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360861710911216640","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"First-Line Immunotherapy for Non–Small-Cell Lung Cancer"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818712564224","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818712738048","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Pembrolizumab-induced focal segmental glomerulosclerosis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865818713310720","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Risk of Nephrotic Syndrome for Non-Steroidal Anti-Inflammatory Drug Users"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865819389629824","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nivolumab-associated Nephrotic Syndrome in a Patient With Renal Cell Carcinoma: A Case Report"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865819390085120","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Minimal change disease associated with anti-PD1 immunotherapy: a case report"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137043851892096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137045351311104","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience"}]},{"@id":"https://cir.nii.ac.jp/crid/1361137046443362560","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699994421815680","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Clinical Features and Outcomes of Immune Checkpoint Inhibitor–Associated AKI: A Multicenter Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1361699995598237696","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Anti-CTLA4 Antibody–Induced Lupus Nephritis"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845607414784","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Renal complications of immune checkpoint blockade"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388846180738944","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Acute kidney injury complicating nephrotic syndrome of minimal change disease"}]},{"@id":"https://cir.nii.ac.jp/crid/2051996266990674688","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Nivolumab-induced membranous nephropathy in a patient with stage Ⅳ lung adenocarcinoma"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1186/s12882-024-03494-1"},{"@type":"KAKEN","@value":"PRODUCT-25023518"},{"@type":"OPENAIRE","@value":"doi_dedup___::aae443d1e48e7956a609937c323a5a37"}]}